摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methoxy-5-(5,6,7-trimethoxy-3,4-dihydronaphthalen-1-yl)phenol | 917591-61-8

中文名称
——
中文别名
——
英文名称
2-Methoxy-5-(5,6,7-trimethoxy-3,4-dihydronaphthalen-1-yl)phenol
英文别名
——
2-Methoxy-5-(5,6,7-trimethoxy-3,4-dihydronaphthalen-1-yl)phenol化学式
CAS
917591-61-8
化学式
C20H22O5
mdl
——
分子量
342.4
InChiKey
DCSQMMULZSZITH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    57.2
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • Combretastatin analogs with tubulin binding activity
    申请人:Pinney G. Kevin
    公开号:US20060293394A1
    公开(公告)日:2006-12-28
    Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.
    已经发现了与康柏他斯汀类似的化合物,它们展示出令人印象深刻的细胞毒性,以及抑制微管聚合的显著能力。这些化合物是治疗人类癌症的优秀临床候选药物。此外,这些配体中的某些作为前药,很可能证明是肿瘤选择性血管靶向化疗药物,或具有血管靶向活性,导致选择性预防和/或破坏非恶性增殖的血管。
  • Combretastatin Analogs with Tubulin Binding Activity
    申请人:PINNEY Kevin G.
    公开号:US20090075943A1
    公开(公告)日:2009-03-19
    Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.
    已经发现了类似于合成静癌素的物质,表现出令人印象深刻的细胞毒性,以及抑制微管聚合的显著能力。这些化合物是治疗人类癌症的优秀临床候选药物。此外,其中某些配体作为前药,可能被证明是肿瘤选择性血管靶向化疗药物,或具有靶向血管活性,导致非恶性增生血管的选择性预防和/或破坏。
  • COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY
    申请人:BAYLOR UNIVERSITY
    公开号:EP1896391B1
    公开(公告)日:2015-08-12
  • US7429681B2
    申请人:——
    公开号:US7429681B2
    公开(公告)日:2008-09-30
  • US8394859B2
    申请人:——
    公开号:US8394859B2
    公开(公告)日:2013-03-12
查看更多